ArticleBMC microbiology2021
Integration of metabolomics and transcriptomics indicates changes in MRSA exposed to terpinen-4-ol.
Article in BMC microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 34 citations in OpenAlex.
- Nano-Enabled Advances in Tea Tree Essential Oil (Materials (Basel, Switzerland) · 2026Review
- Antibacterial mechanisms of terpinen-4-ol against Aeromonas hydrophila.Archives of microbiology · 2026Article
- Multitarget Mechanisms of (‒)‒Epigallocatechin-3-Gallate Against MRSA: From SraP L-Lectin Targeting to Synergistic Antibiotic Effects.Pathogens (Basel, Switzerland) · 2026Article
- Synergistic antipersister, efflux inhibitory & antibiofilm activities of vaginal Lactobacillus-derived postbiotics against UPEC: toward a novel therapeutic for utis.Scientific reports · 2026Article
- Proanthocyanidins inhibit methicillin-resistantCurrent research in food science · 2026Article
- Tripterhyponoid A fromMolecules (Basel, Switzerland) · 2025Article
- Phytochemical-Loaded Thermo-responsive Liposome for Synergistic Treatment of Methicillin-ResistantBiomaterials research · 2025Article
- Essential oils: a potential alternative with promising active ingredients for pharmaceutical formulations in chronic wound management.Inflammopharmacology · 2024Review
- Anti-Antibiotics (Basel, Switzerland) · 2024Article
- Metabolomic Profiling of Aqueous Humor from Pathological Myopia Patients with Choroidal Neovascularization.Metabolites · 2023Article
- Comprehensive Study of Components and Antimicrobial Properties of Essential Oil Extracted fromAntibiotics (Basel, Switzerland) · 2023Article
- First Evidence of a Combination of Terpinen-4-ol and α-Terpineol as a Promising Tool against ESKAPE Pathogens.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study investigated the effects of terpinen-4-ol on methicillin-resistant Staphylococcus aureus (MRSA) and its biofilm, and the possible mechanisms governing this effect.
resultsWe observed that terpinen-4-ol has good antibacterial activity and inhibits the formation of MRSA biofilm. The MIC and MBC values for terpinen-4-ol against S. aureus were 0.08% ~ 0.32%. And terpinen-4-ol at 0.32% could kill all bacteria and clear all biofilms. Untargeted metabolomic and transcriptomic analyses showed that terpinen-4-ol strongly inhibited DNA and RNA biosynthesis in MRSA at 2 h after treatment by affecting genes and metabolites related to purine and pyrimidine metabolic pathways. Some differential genes which play important roles in DNA synthesis and the production of eDNA from biofilm exposed to terpinen-4-ol was also significantly decreased compared with that of the control.
conclusionsTerpinen-4-ol has good antibacterial activity and significantly inhibits the formation of MRSA biofilm by inhibiting purine and pyrimidine metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.